Bliss GVS Pharma Limited reported earnings results for the third quarter and nine months ended December 31, 2022. For the third quarter, the company reported sales was INR 2,057.17 million compared to INR 2,162.58 million a year ago. Revenue was INR 2,113.64 million compared to INR 2,222.94 million a year ago. Net income was INR 279.42 million compared to net loss of INR 501.12 million a year ago. Basic earnings per share from continuing operations was INR 2.68 compared to basic loss per share from continuing operations of INR 4.83 a year ago. Diluted earnings per share from continuing operations was INR 2.64.
For the nine months, sales was INR 5,668.09 million compared to INR 5,803.91 million a year ago. Revenue was INR 5,816.17 million compared to INR 5,996.94 million a year ago. Net income was INR 675.15 million compared to net loss of INR 45.92 million a year ago. Basic earnings per share from continuing operations was INR 6.49 compared to basic loss per share from continuing operations of INR 0.44 a year ago. Diluted earnings per share from continuing operations was INR 6.39.